[
  {
    "ticker": "REPL",
    "company": "Replimune Group",
    "drug": "RP1 + nivolumab (advanced melanoma)",
    "event_date": "2026-04-10",
    "pdufa_type": "Priority BLA",
    "entry_date": "2026-02-09",
    "exit_date": "2026-04-03",
    "days_until_entry": 37,
    "current_price": 9.14,
    "trend": "Strong uptrend (+86.51% monthly)",
    "cash_position_m": 536.5,
    "runway_months": 20,
    "risk_level": "LOW",
    "recommendation": "STRONG BUY",
    "rationale": "Ideal entry timing (37 days). Strong cash position ($536M, 20mo runway). Recent FDA BLA resubmission acceptance. Price momentum strong post-acceptance announcement. No financial dilution risk."
  },
  {
    "ticker": "AXSM",
    "company": "Axsome Therapeutics",
    "drug": "AXS-05 (Alzheimer's disease agitation)",
    "event_date": "2026-04-30",
    "pdufa_type": "Priority Review (Breakthrough Therapy)",
    "entry_date": "2026-02-29",
    "exit_date": "2026-04-23",
    "days_until_entry": 57,
    "current_price": 152.05,
    "trend": "Uptrend (volatile)",
    "cash_position_m": 325.3,
    "runway_months": 99,
    "risk_level": "LOW",
    "recommendation": "BUY",
    "rationale": "Good entry timing (57 days). Already commercializing Auvelity ($500M+ annualized). Approaching cash flow positivity. Major market opportunity ($3B peak sales potential). Breakthrough Therapy designation reduces approval risk."
  },
  {
    "ticker": "RYTM",
    "company": "Rhythm Pharmaceuticals",
    "drug": "Imcivree (acquired hypothalamic obesity)",
    "event_date": "2026-03-20",
    "pdufa_type": "Priority Review (sNDA)",
    "entry_date": "2026-01-19",
    "exit_date": "2026-03-13",
    "days_until_entry": 16,
    "current_price": 112.14,
    "trend": "Strong uptrend",
    "cash_position_m": 416.1,
    "runway_months": 24,
    "risk_level": "LOW",
    "recommendation": "HOLD/BUY",
    "rationale": "Entry window opening soon (16 days). Exceptional cash position ($416M, 24mo runway). Strong revenue growth (+54% YoY, $51M Q3). Commercial product already approved for age 12+. Rare disease orphan status."
  },
  {
    "ticker": "ALDX",
    "company": "Aldeyra Therapeutics",
    "drug": "Reproxalap (dry eye disease)",
    "event_date": "2026-03-16",
    "pdufa_type": "Standard NDA (3rd attempt)",
    "entry_date": "2026-01-15",
    "exit_date": "2026-03-09",
    "days_until_entry": 12,
    "current_price": 4.72,
    "trend": "Consolidating (near 52-week low)",
    "cash_position_m": 75.3,
    "runway_months": 12,
    "risk_level": "MEDIUM",
    "recommendation": "SPECULATIVE BUY",
    "rationale": "Entry window imminent (12 days). Binary event risk: 2 prior CRLs but FDA provided draft label. Small-cap with 12-mo runway (may need financing). High risk/high reward ($7-13 PT vs $4.72 current). Market underpricing due to skepticism."
  }
]
